Abstract:Unprecedented asymmetric copper-catalysed addition of ZnEt2 (ZnBu2)
the (S,S) isomer is twice as active towards pancreatic, breast and colon cancer cell lines as its (R,R) enantiomer at 24 h.Asymmetric copper-catalysed 1,4-additions of organozincs, especially ZnEt2, to enones (e.g. ArCH=CHAc) have become commonplace in the last 10 years (Scheme 1a). [1] Although they contain an equally powerful anion accepting group (C5H4), equivalent copper-catalysed enantioselective carbocupration of pentafulvenes 1 is unknown (Scheme 1b). Such methodology could, if realised, provide rapid access to enantio-enriched substituted cyclopentadienyl ligands 2 having many applications in synthesis, catalysis [2] and biology. [3] To give just one specific example, the micromolar active anti-cancer titanocene dichloride 3 (presently known only as a mixture of stereoisomers) [3] would become available as single enantiomers, facilitating biological screening and potentially access to clinical trial candidates in time.Scheme 1. Exemplary common Cu(I)-catalysed asymmetric 1,4-addition vs. unknown carbozination and applications.